β-Secretase enzyme (BACE) inhibition has been proposed as a priority treatment mechanism for Alzheimer’s disease (AD), but treatment initiation may need to be very early. This evidence concerns the gene BACE1 and early-onset autosomal dominant Alzheimer disease.